Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Xenetic Biosciences (XBIO) Research & Development (2023 - 2025)

Xenetic Biosciences' Research & Development history spans 4 years, with the latest figure at $500000.0 for Q4 2025.

  • For Q4 2025, Research & Development fell 52.03% year-over-year to $500000.0; the TTM value through Dec 2025 reached $2.8 million, down 15.09%, while the annual FY2025 figure was $3.1 million, 6.78% down from the prior year.
  • Research & Development reached $500000.0 in Q4 2025 per XBIO's latest filing, down from $756482.0 in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $1.0 million in Q4 2024 to a low of $367985.0 in Q3 2024.
  • Average Research & Development over 3 years is $797930.4, with a median of $891136.0 recorded in 2023.
  • Peak YoY movement for Research & Development: tumbled 63.94% in 2024, then surged 105.57% in 2025.
  • A 3-year view of Research & Development shows it stood at $975628.0 in 2023, then grew by 6.83% to $1.0 million in 2024, then tumbled by 52.03% to $500000.0 in 2025.
  • Per Business Quant, the three most recent readings for XBIO's Research & Development are $500000.0 (Q4 2025), $756482.0 (Q3 2025), and $656557.0 (Q2 2025).